Data Animal Data In pregnant rats given twice weekly subcutaneous doses of 0.02, 0.1, and 0.5 mg/kg tirzepatide (0.03-, 0.07-, and 0.5-fold the MRHD of 15 mg once weekly based on AUC) during organogenesis, increased incidences of external, visceral, and skeletal malformations, increased incidences of visceral and skeletal developmental variations, and decreased fetal weights coincided with pharmacologically-mediated reductions in maternal body weights and food consumption at 0.5 mg/kg
Participants were monitored for changes in heart rate and other vital signs
There are rapid home tests that can detect changes in vaginal pH or identify Candida-specific components, and some over-the-counter kits allow for vaginal swabs to be mailed to a lab
Ozempic and the Risk of Severe Side Effects: Kidney Injury, Thyroid Cancer, and More What are the side effects of GLP-1s